Pharmaceutical Industry News Archive
Get news By email or subscribe to our News feeds.
April 2009
April 1
FDA Acts to Halt Marketing of Certain Unapproved Prescription Narcotic Drugs
FDA Sends Boehringer Ingelheim Roxane Inc. Warning Letter for Marketing Unapproved New Drugs Roxanol Oral Solution, 20 mg/ml and Roxicodone Tablets, 5 mg
TorreyPines Therapeutics Reduces Workforce to Three Employees
Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
Appeals Court Affirms That J&J Stents Infringe Boston Scientific Patent; Claims Against TAXUS Liberte Dismissed
Medical Leaders to Propose Curbs on Conflict of Interest
Solvay Confirms It Is Proceeding With An Analysis Of Various Options For Its Pharmaceutical Activities
Global Market For Pediatric Healthcare Worth $79.2 Billion In 2013
Stanford Medical School to Provide Online Disclosure of Faculty's Consulting Activities
April 2
Elan and Wyeth Plan to Amend Bapineuzumab Phase 3 Protocols
Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL (lanthanum carbonate) Patents
Astellas Appoints New US President and CEO
Pfizer Discontinues One Sunitinib Phase 3 Trial in Advanced Breast Cancer; Other Advanced Breast Cancer Trials Continue
Pfizer Development Pipeline Shows Advances In High-Priority Disease Areas
April 3
Charles River to Acquire Piedmont Research Center
PPD Acquires Magen BioSciences
R&D Directions’ Data Management For Clinical Trials Webinar Details Data Capture And Management Strategies
AstraZeneca's David Brennan Elected PhRMA Board Chairman
Pfizer Receives Request for Additional Information from FTC Regarding Proposed Acquisition of Wyeth
Pfizer Becomes The First Pharmaceutical Company To Be Accredited For Protection Of Human Rights In Clinical Research
April 6
U.S. Appeals Court Issues Ruling in Support of Lilly in Ariad Patent Litigation
Bristol-Myers Squibb Announces Extension of U.S. Agreement for Abilify and Establishment of an Oncology Collaboration with Otsuka
Statement Regarding Possible Offer for Renovo
FDA Sends Letters to 14 Companies Regarding Internet Ads
CVS Caremark Study Documents Changes in Prescription Drug Use to Treat High Blood Pressure, High Cholesterol and Diabetes in Children and Adolescents
April 7
Former Bristol-Myers Squibb Senior Executive Pleads Guilty for Role in Dishonest Dealings with the Federal Government
Diabetes and Blood Pressure Medication Prescriptions Increase Among Children and Teens
Pfizer Announces Operating Structure and Select Senior Leadership Posts to Be Effective Immediately Upon Close of Wyeth Acquisition
AstraZeneca Files Suit Against Apotex for a Declaratory Judgment of Infringement Against Pulmicort Respules Patents
AMA Announces Staff Reductions
2008 Sees Significant Rise in Prescription Abandonment and Uptake of Generics
Avalon Pharmaceuticals Receives Audit Opinion Containing Going Concern Statement
April 8
Manhattan Research Releases Digital DTC Relevance Rankings, Revealing Which Condition Groups Are Most Likely to Adopt eHealth
DDB Worldwide and M/A/R/C Research Find in Time of Economic Crisis: Health Is the New Wealth
Mylan Announces Clarinex Settlement Agreement
Governor, Legislature Support Sales Tax Exemptions For Clinical Trials and Free Samples of Drugs
J. Michael Cook to Retire from Lilly Board of Directors
Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market
April 9
FDA Statement on the Voluntary Withdrawal of Raptiva From the U.S. Market
Inclusion of Untested Cancer Drug Clouds BC Government Announcement Recognizing Needs of Persons With Wet Age-Related Macular Degeneration
Sanofi-aventis to Acquire Medley in Brazil
New JHM Policies Tighten Rules on Industry Interactions
Heartburn Medications do not Ease Asthma Symptoms
April 10
April 13
April 14
April 15
Sanofi-aventis to Acquire BiPar Sciences, a US Biopharmaceutical Company
Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009
Gilead Sciences Successfully Completes Tender Offer for Shares of CV Therapeutics With Over 88 Percent of Shares Tendered
Significant Growth in the Pharmaceutical Industry Drives China Into Global Spotlight, Finds New PricewaterhouseCoopers Report
Roche and Genentech Announce Organizational and Leadership Decisions
April 16
Baxter Announces Strong First Quarter Financial Results
GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company
Biogen Idec Receives Approval for Tysabri High Titer Production
Roche strongly outperforms market in first quarter
Drug Marketing Disclosures Show Nearly $3 Million In Payments To Vermont Prescribers
Infinity Halts RING Trial in Advanced Gastrointestinal Stromal Tumors
PhRMA Statement on AARP Report
Kalorama Anticipates Increase in Rx-to-OTC Switches as Result of Recession
StemCells, Inc. Announces License Agreement with Major Pharmaceutical Company Covering Gene Insertion Technology
April 17
Amylin Pharmaceuticals Reports First Quarter Financial Results
Court Grants AstraZeneca Temporary Restraining Order Against Apotex in Pulmicort Respules Patent Litigation
One in Eight Pharmaceutical Sales Visits Are Impossible to Achieve, Says New Report from ZS
Discontinuation of Development of AC-3933, Therapeutic Agent for Dementia
Chiltern Acquires Brazil-Based Clinical Research Organization Vigiun
ChemDiv Group Acquires Prudentas Through ChemRar High Tech Center
April 20
April 21
Schering-Plough Reports Financial Results for 2009 First Quarter
Merck Announces First-Quarter 2009 Financial Results
Healthline Launches Internet's First Treatment Search Tool; Healthline DocSearch Allows Consumers to Search; Compare and Connect to Relevant Specialists
Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation
Boehringer Ingelheim Maintains its Growth Path in 2008
Sanofi-Aventis Builds New Manufacturing Base in Hangzhou
Sanofi-Aventis Announces New Investment in China to Locally Produce Lantus SoloSTAR
Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile Infection
Icahn Responds to Cook and Wilson
Immtech to Reorganize Research and Development Operations
April 22
April 23
Med Ad News Honors Healthcare Advertisers at 20th Annual Manny Awards
Pharmaceuticals Delivers Strong Underlying Growth in First Quarter of 2009 as Novartis Continues to Rejuvenate Product Portfolio
Updated FDA Action on Plan B (levonorgestrel) Tablets
IMS Health Lowers 2009 Global Pharmaceutical Market Forecast to 2.5 – 3.5 Percent Growth
Icahn Asks Amylin to Allow Discussions With Eastbourne
April 24
Amylin Issues Statement in Response to Carl Icahn
Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
Sen. Grassley Works for Prescription Drug and Medical Device Safety
Iressa (Gefitinib) Recommended for Approval for the Treatment of Non-Small Cell Lung Cancer in Europe
Ad hoc: Jerini AG: Management Board and Supervisory Board Decide to Wind Down the Operations of Jerini Ophthalmic, Inc.
Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis C
Abbott Annual Meeting Highlights Outstanding 2008 Results, Continued Strong Outlook
Eastbourne Capital Comments on Recent Developments Regarding Amylin Pharmaceuticals
Regional Biotech Association Warns Legislation Would Make VT Least Friendly State in Nation for Biotechnology and Life Sciences
Sucampo Acquires Rights to Rescula for U.S. and Canada
April 27
Q1/2009: Merck Revenues Remain Stable at € 1.9 Billion
Biogen Idec Board Recommends Shareholders Elect Directors with Record of Success in Enhancing the Value of the Company
SDI Reports Sixty-Seven Percent of Physicians Surveyed Have Positive Attitude Toward Electronic Promotional Activities
Concerned Shareholders of Biovail Announce - Independent Nominees for Election to Biovail Board of Directors - A Focused Commitment to Governance at Biovail
April 28
Bristol-Myers Squibb Reports Excellent First Quarter Financial Results; Delivers on Two Significant Strategic Initiatives
Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer
Pfizer Reports First-Quarter 2009 Results; Reaffirms Full-Year 2009 Financial Guidance for Revenues and Adjusted Results
Kyowa Hakko Kirin Fiscal 2008 Sales up 17.4%, Operating Income up 15.2%
bioXell S.p.A (CH) - BioXell announces restructuring following review of portfolio
FDA Authorizes Emergency Use of Influenza Medicines, Diagnostic Test in Response to Swine Flu Outbreak in Humans
Pharmaceutical Industry Significantly Improves in Harris Interactive Reputation Study
Genaera Corporation Announces Approval of Plan of Liquidation and Dissolution by Board of Directors
April 29
PhRMA Applauds Kathleen Sebelius’ Confirmation as HHS Secretary
Sanofi-aventis Announces Good First-quarter 2009 Performance
Wyeth Reports Earnings Results for the 2009 First Quarter
MRI Data Showing Tysabri Promoted Remyelination Presented at the 61st Annual Meeting of the American Academy of Neurology
Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
ZymoGenetics Announces Workforce Reduction and Restructuring
Statement from Roche Canada re: Supply of Tamiflu (oseltamivir)
Rx Response Raised to 'Alert Status' in Response to Growing Swine Flu Threat
April 30
Interim financial report for the period 1 January 2009 to 31 March 2009 (30 April 2009)
AstraZeneca PLC First Quarter Results 2009
Shire Begins the Year with a Strong Performance
FDA MedWatch - Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B): Strengthened warnings in product labeling
Pharmaceutical Companies Are Looking to Reshape the Multi-Billion Dollar Drug Industry, Says New PricewaterhouseCoopers Report
FDA approves Exforge HCT - the only high blood pressure treatment to combine three medications in a single pill
Allergan Comments on FDA Requested Class Labeling for Botulinum Toxin Treatments in Connection with Approval of Dysport
